Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement (original) (raw)

Relevant more generic / specialised reporting guidelines
(i.e. main generic guideline or extension to a generic guideline)

Generic
PRISMA 2020 Statement: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

PLoS Med. 2021;18(3):e1003583. PMID: 33780438
BMJ 2021;372:n71. PMID: 33782057
Int J Surg. 2021:105906. PMID: 33789826
J Clin Epidemiol. 2021:S0895-4356(21)00073-1. PMID: 33789819
Syst Rev. 2021;10(1):89. PMID: 33781348

Specialised
PRISMA-Equity: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H; PRISMA-Equity Bellagio group. PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med. 2012;9(10):e1001333. PMID: 23222917

Welch V, Petticrew M, Petkovic J, Moher D, Waters E, White H, Tugwell P; PRISMA-Equity Bellagio group. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): explanation and elaboration.
Int J Equity Health. 2015;14(1):92. PMID: 26450828
J Clin Epidemiol. 2015. PMID: 26348799

PRISMA-Abstracts 2020: The PRISMA 2020 for Abstracts reporting guideline is contained within the main PRISMA 2020 Statement paper.

PRISMA-P: Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. PMID: 25554246

PRISMA extension for network meta-analyses: Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162(11):777-784. PMID: 26030634

PRISMA-harms: Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. PMID: 26830668

PRISMA-CI: Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P; Complex Interventions Workgroup. AHRQ Series on Complex Intervention Systematic Reviews - Paper 6: PRISMA-CI Extension Statement & Checklist. J Clin Epidemiol. 2017. PMID: 28720516

PRISMA-DTA: McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-396. PMID: 29362800

PRISMA-ScR: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018. PMID: 30178033

PRISMA-A: Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, Wu T, Shang H, Lee MS, Wei D, Tian J, Ma B, Wang Y, Tian G, Yang K. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. PMID: 31405367

PRISMA-DTA for Abstracts: Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leeflang MM, Macaskill P, McGrath TA, Moher D, Reitsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, Thombs B, Bossuyt PM, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. BMJ. 2021;372:n265. PMID: 33722791

PRISMA-CHM: Zhang X, Tan R, Lam WC, Yao L, Wang X, Cheng CW, Liu F, Chan JC, Aixinjueluo Q, Lau CT, Chen Y, Yang K, Wu T, Lyu A, Bian Z. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1279-1313. PMID: 32907365

PRISMA-M 2020: Zhang X, Tan R, Lam WC, Cheng CW, Yao L, Wang XQ, Li SY, Aixinjueluo QY, Yang KH, Shang HC, Wu TX, Lyu AP, Bian ZX. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev. 2020;9(1):247. PMID: 33100229

PRISMA-S: Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB; PRISMA-S Group. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.
Syst Rev. 2021;10(1):39. PMID: 33499930
J Med Libr Assoc. 2021;109(2):174-200. PMID: 34285662

PRISMA-COSMIN for OMIs: Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, Baba A, Butcher NJ, Smith M, Hofstetter C, Lee Aiyegbusi O, Berardi A, Farmer J, Haywood KL, Krause KR, Markham S, Mayo-Wilson E, Mehdipour A, Ricketts J, Szatmari P, Touma Z, Moher D, Offringa M. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
J Clin Epidemiol. 2024:111422. PMID: 38849061
Qual Life Res. 2024. PMID: 38980635
Health Qual Life Outcomes. 2024;22(1):48. PMID: 38978063
J Patient Rep Outcomes. 2024;8(1):64. PMID: 38977535